Home » Stocks » ZYXI

Zynex, Inc. (ZYXI)

Stock Price: $13.62 USD 0.20 (1.49%)
Updated November 23, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 473.17M
Revenue (ttm) 68.68M
Net Income (ttm) 10.23M
Shares Out 34.74M
EPS (ttm) 0.30
PE Ratio 45.40
Forward PE 43.29
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $13.62
Previous Close $13.42
Change ($) 0.20
Change (%) 1.49%
Day's Open 13.50
Day's Range 13.18 - 13.67
Day's Volume 339,302
52-Week Range 7.51 - 29.73

More Stats

Market Cap 473.17M
Enterprise Value 436.84M
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 34.74M
Float 19.45M
EPS (basic) 0.31
EPS (diluted) 0.30
FCF / Share 0.11
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.20%
FCF Yield 0.81%
Payout Ratio n/a
Shares Short 6.18M
Short Ratio 6.13
Short % of Float 31.76%
Beta 0.91
PE Ratio 45.40
Forward PE 43.29
P/FCF Ratio 123.71
PS Ratio 6.89
PB Ratio 8.58
Revenue 68.68M
Operating Income 11.68M
Net Income 10.23M
Free Cash Flow 3.83M
Net Cash 36.33M
Net Cash / Share 1.05
Gross Margin 53.55%
Operating Margin 17.01%
Profit Margin 14.90%
FCF Margin 5.57%
ROA 16.28%
ROE 28.99%
ROIC 64.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$25.75*
(89.06% upside)
Low
22.5
Current: $13.62
High
30.3
Target: 25.75
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue45.4731.9223.4313.3111.6411.1221.6847.1539.6828.49
Revenue Growth42.47%36.21%76.01%14.36%4.71%-48.73%-54.01%18.84%39.29%-
Gross Profit36.6625.8818.619.806.703.5113.5438.3832.3123.28
Operating Income11.0710.378.940.64-2.48-5.70-7.6010.228.635.96
Net Income9.499.557.370.07-2.91-6.20-7.301.551.560.35
Shares Outstanding32.4432.5032.1631.2731.2731.2131.1531.0630.7530.55
Earnings Per Share0.280.280.22--0.09-0.20-0.230.050.050.01
EPS Growth0%27.27%-----0%400%-
Dividend Per Share-0.07---0.15----
Operating Cash Flow6.309.418.261.770.340.96-0.38-0.88-0.36-0.67
Capital Expenditures-0.16-1.08-0.09-0.230.01-0.27-0.64-0.76-1.27-0.67
Free Cash Flow6.148.338.171.540.350.69-1.03-1.64-1.63-1.34
Cash & Equivalents14.3710.445.940.300.060.070.720.990.960.78
Total Debt4.683.660.353.034.334.836.066.163.681.69
Net Cash / Debt9.696.785.58-2.72-4.26-4.77-5.34-5.17-2.72-0.91
Assets28.2819.258.934.093.707.1117.2225.9421.7915.70
Liabilities8.629.964.037.897.778.3812.3713.8811.657.52
Book Value19.749.384.99-3.71-3.98-1.204.8812.0510.148.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zynex, Inc.
Country United States
Employees 283
CEO Thomas Sandgaard

Stock Information

Ticker Symbol ZYXI
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: ZYXI

Description

Zynex, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.